Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review

Critical Reviews in Oncology/Hematology

Volumn 90, Issue 3, 2014, Pages 190-199

  Lyman, Gary H ^a   Abella, Esteban ^b   Pettengell, Ruth ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b AMGEN INC   (United States)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer; Chemotherapy; Febrile neutropenia; Risk factor

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; MANNOSE BINDING LECTIN 2; METHOTREXATE; PACLITAXEL; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABNORMAL LABORATORY RESULT; ADVANCED CANCER; AGE; BODY MASS; BODY SURFACE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; COMORBIDITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FGFR4 GENE; GENDER; GENETIC ASSOCIATION; GENETIC RISK; HEALTH STATUS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MBL2 GENE; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT PLANNING; COMPLICATION; NEOPLASMS;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEBRILE NEUTROPENIA; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 84899930607     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.12.006     Document Type: Review

References (50)

1. Kuderer N.M., Dale D.C., Crawford J., Cosler L.E., Lyman G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006, 106:2258-2266.
2. Lyman G.H., Michels S.L., Reynolds M.W., Barron R., Tomic K.S., Yu J. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 2010, 116:5555-5563.
3. Crawford J., Dale D.C., Lyman G.H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004, 100:228-237.
4. Schilling M.B., Parks C., Deeter R.G. Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study. Exp Ther Med 2011, 2:859-866.
5. Crawford J., Dale D.C., Kuderer N.M., Culakova E., Poniewierski M.S., Wolff D., et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 2008, 6:109-118.
6. Chang J. Chemotherapy dose reduction and delay in clinical practice. evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 2000, 36(Suppl 1):S11-S14.
7. Dale D.C., McCarter G.C., Crawford J., Lyman G.H. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw 2003, 1:440-454.
8. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Myeloid Growth Factors. v1.2012.
9. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
10. Aapro M.S., Bohlius J., Cameron D.A., Dal Lago L., Donnelly J.P., Kearney N., et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011, 47:8-32.
11. Lyman G.H., Lyman C.H., Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005, 10:427-437.
12. Salar A., Haioun C., Rossi F.G., Duehrsen U., Pettengell R., Johnsen H.E., et al. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. Leuk Res 2012, 36:548-553.
13. Lyman G.H., Morrison V.A., Dale D.C., Crawford J., Delgado D.J., Fridman M. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receivng CHOP chemotherapy. Leuk Lymphoma 2003, 44:2069-2076.
14. Pettengell R., Bosly A., Szucs T.D., Jackisch C., Leonard R., Paridaens R., et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol 2009, 144:677-685.
15. Laskey R.A., Poniewierski M.S., Lopez M.A., Hanna R.K., Secord A.A., Gehrig P.A., et al. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer. Gynecol Oncol 2012, 125:625-630.
16. Lyman G.H., Delgado D.J. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003, 98:2402-2409.
17. Lyman G.H. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 2009, 7:99-108.
18. Rajan S.S., Stearns S.C., Lyman G.H., Carpenter W.R. Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. Breast Cancer Res Treat 2011, 130:255-266.
19. Ray-Coquard I., Borg C., Bachelot T., Sebban C., Philip I., Clapisson G., et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003, 88:181-186.
20. Ozawa K., Minami H., Sato H. Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients. Cancer Chemother Pharmacol 2008, 62:551-557.
21. Alexandre J., Rey E., Girre V., Grabar S., Tran A., Montheil V., et al. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol 2007, 18:168-172.
22. Shayne M., Culakova E., Wolff D., Poniewierski M.S., Dale D.C., Crawford J., et al. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer 2009, 115:5319-5328.
23. Crawford J., Glaspy J.A., Stoller R.G., Tomita D.K., Vincent M.E., McGuire B.W., et al. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther 2005, 3:36-46.
24. Scott S.D., Chrischilles E.A., Link B.K., Delgado D.J., Fridman M., Stolshek B.S. Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapy. J Manag Care Pharm 2003, 9:15-21.
25. Hosmer W., Malin J., Wong M. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer 2011, 19:333-341.
26. Ng J.H., Ang X.Y., Tan S.H., Tao M., Lim S.T., Chan A. Breakthrough febrile neutropenia and associated complications in Non-Hodgkin's lymphoma patients receiving pegfilgrastim. Acta Haematol 2011, 125:107-114.
27. Jenkins P., Freeman S. Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol 2009, 20:34-40.
28. Jenkins P., Scaife J., Freeman S. Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer. Ann Oncol 2012, 23:1766-1771.
29. Phippen N.T., Lowery W.J., Barnett J.C., Hall L.A., Landt C., Leath C.A. Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: a pilot study. Gynecol Oncol 2011, 123:360-364.
30. Hurria A., Brogan K., Panageas K.S., Jakubowski A., Zauderer M., Pearce C., et al. Change in cycle 1 to cycle 2 haematological counts predicts toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Drugs Aging 2005, 22:709-715.
31. Lyman G.H., Kuderer N.M., Crawford J., Wolff D.A., Culakova E., Poniewierski M.S., et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011, 117:1917-1927.
32. Moreau M., Klastersky J., Schwarzbold A., Muanza F., Georgala A., Aoun M., et al. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol 2009, 20:513-519.
33. Borg C., Ray-Coquard I., Philip I., Clapisson G., Bendriss-Vermare N., Menetrier-Caux C., et al. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 2004, 101:2675-2680.
34. Choi C.W., Sung H.J., Park K.H., Yoon S.Y., Kim S.J., Oh S.C., et al. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. Am J Hematol 2003, 73:263-266.
35. Castagnola E., Garre M.L., Bertoluzzo L., Pignatelli S., Pavanello M., Caviglia I., et al. Epidemiology of febrile neutropenia in children with central nervous system tumor: results from a single center prospective study. J Pediatr Hematol Oncol 2011, 33:e310-e315.
36. Meyerhardt J.A., Kwok A., Ratain M.J., McGovren J.P., Fuchs C.S. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2004, 22:1439-1446.
37. Rivera E., Haim Erder M., Fridman M., Frye D., Hortobagyi G.N. First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study. Breast Cancer Res 2003, 5:R114-R120.
38. Chan A., Chen C., Chiang J., Tan S.H., Ng R. Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. Support Care Cancer 2012, 20:1525-1532.
39. Griggs J.J., Mangu P.B., Anderson H., Balaban E.P., Dignam J.J., Hryniuk W.M., et al. Appropriate chemotherapy dosing for obese adult patients with cancer: ASCO practice guideline. J Clin Oncol 2012, 30:1553-1561.
40. Lyman G.H., Sparreboom A. Chemotherapy dosing in overweight and obese patients with cancer. Nat Rev Clin Oncol 2013, 10:451-459.
41. Hershman D., Hurley D., Wong M., Morrison V.A., Malin J.L. Impact of primary prophylaxis on febrile neutropenia within community practices in the US. J Med Econ 2009, 12:203-210.
42. Hansson E.K., Friberg L.E. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia. Cancer Chemother Pharmacol 2012, 69:881-890.
43. Kuderer N.M., Dale D.C., Crawford J., Lyman G.H. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007, 25:3158-3167.
44. Cullen M.H., Billingham L.J., Gaunt C.H., Steven N.M. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol 2007, 25:4821-4828.
45. Sharma S., Rezai K., Driscoll D., Odunsi K., Lele S. Characterization of neutropenic fever in patients receiving first-line adjuvant chemotherapy for epithelial ovarian cancer. Gynecol Oncol 2006, 103:181-185.
46. McLeod H.L., Sargent D.J., Marsh S., Green E.M., King C.R., Fuchs C.S., et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 2010, 28:3227-3233.
47. Okishiro M., Kim S.J., Tsunashima R., Nakayama T., Shimazu K., Shimomura A., et al. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide. Breast Cancer Res Treat 2012, 132:947-953.
48. van der Bol J.M., de Jong F.A., van Schaik R.H., Sparreboom A., van Fessem M.A., van de Geijn F.E., et al. Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia. Oncologist 2010, 15:1063-1072.
49. Vulsteke C., Lambrechts D., Dieudonné A., Hatse S., Brouwers B., van Brussel T., et al. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol 2013, 24:1513-1525.
50. Schwenkglenks M., Bendall K.L., Pfeil A.M., Szabo Z., Pettengell R. External validation of a risk model of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma. Leuk Lymphoma Early 2013, 54:2426-2432.